Click here for a recording of the investor webinar on 9 May 2024, hosted by CEO & MD, Dr Kilian Kelly

In case you missed it, Dr Kilian Kelly presented to brokers, fund managers, and high net-worth investors over lunch at the Establishment Ballroom, outlining Cynata's recent clinical trial milestones. Watch the presentation here

Off the back of a string of positive announcements - DFU trial initial data, new CBO and first patient treated in aGVHD trial - Cynata CEO Dr Kilian Kelly sat down with Finance News Network to discuss The Company's milestones. Watch the interview below

In early March, the first patient was enrolled and treated in Cynata’s Phase 2 clinical trial of CYP-001 in high-risk acute graft versus host disease (aGvHD).

Learn more here: https://bit.ly/4b0nkG7

Cynata has updated the market on the positive progress of its diabetic foot ulcers clinical trial.

Read Stockhead’s coverage here https://bit.ly/3P0mb8N